Bacteria that aid immunotherapy: what 2026 holds for cancer treatment

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. The sci-fi-sounding idea That the bacteria in your gut could i.

Bacteria that help immunotherapy: what 2026 brings to cancer treatment

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. The idea that sounds like science fiction That the bacteria in.

Mirai: The AI That Outperforms Breast Density in Predicting Breast Cancer at 5 Years

A deep learning model applied to screening mammograms (Mirai) predicts breast cancer risk at 5 years with AUROC 0.71, compared to 0.53 for BI-RADS breast density PMID: 42554691. Th.

Fatigue with Adjuvant/Neoadjuvant Immunotherapy: +21% vs Placebo, Patients Notice It

Immunotherapy with immune checkpoint inhibitors (ICIs) in curative-intent settings (adjuvant/neoadjuvant) increases fatigue by 21% versus placebo (RR 1.21; 95% CI 1.08-1.35) PMID.

Second cancers: which drugs truly prevent them (and which do not)

An increasing number of people survive cancer. That is good news, but it has a hidden side: the long-term risk of developing a second primary cancer (SPC), distinct from the first.

Radiotherapy + immunotherapy: the key is not just how much dose, but how it’s distributed

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. What if radiotherapy could be designed to awaken the immune sy.

Guided missiles against cancer: T cell engagers and antibody-drug conjugates

When Checkpoints Fall Short Checkpoint inhibitors changed oncology forever. But not for everyone: there are patients with primary resistance, tumors that relapse, and toxicities th.

Tucatinib + T-DXd in Advanced HER2+: Two Bullets for the Same Target (HER2CLIMB-04)

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. What if we attack HER2 twice at once? In advanced HER2+ breast.

Gynecologic Cancer: Treatment Is No Longer Just Chemotherapy

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. When Chemotherapy Stopped Being the Only Answer For decades, a.

Automated breast ultrasound (ABUS) and AI: better classification of BI-RADS 3–4 lesions without triggering unnecessary biopsies

Title: Automated breast ultrasound (ABUS) and AI: better classification of BI-RADS 3–4 lesions without triggering unnecessary biopsies Type: A (Medical imaging AI) Tags: breast ult.

HER2 Heterogeneity: Why Some Tumors Escape Targeted Therapy (and What New Targets Emerge)

Title: HER2 Heterogeneity: Why Some Tumors Escape Targeted Therapy (and What New Targets Emerge) Type: A (mechanism/basic-translational) Tags: HER2, intratumoral heterogeneity, res.

Oncology nutrition: a toolkit and checklist that primary care dietitians can use now

Title: Oncology Nutrition: A Toolkit and Checklist That Primary Care Dietitians Can Use Now Type: C (implementation/supportive care) Tags: oncology nutrition, dietitians, toolkit.

Weight loss in breast cancer survivors: when coaching isn’t enough, medication helps (A-NEW study)

Title: Weight loss in breast cancer survivors: when coaching is not enough, the drug helps (A-NEW study) Type: B (clinical / real-world) Tags: breast cancer survivors, obesity, wei.

Tucatinib + T-DXd in advanced HER2+: two bullets for the same target (HER2CLIMB-04)

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. What if we attack HER2 twice at once? In advanced HER2+ breast.

Exercise and the oncologic brain: the evidence is no longer anecdotal (network meta-analysis)

Title: Exercise and the oncological brain: the evidence is no longer anecdotal (network meta-analysis) Type: B (clinical / supportive care) Tags: exercise, cognition, oncology, reh.

AI on H&E histology predicts invasive bladder cancer prognosis without genomics

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. Pathology is no longer just the pathologist’s domain Muscle-in.

Menopause does not modulate the benefit of CDK4/6 inhibitors in adjuvancy: phase III meta-analysis

Title: Menopause does not modulate the benefit of CDK4/6 inhibitors in adjuvant setting: phase III meta-analysis Type: B (clinical / real-world) Tags: CDK4/6, HR+ breast cancer, ad.

AI in mammography: does not prolong reading and detects more cancers

Title: AI in mammography: does not prolong reading time and detects more cancers — prospective alternating months study Type: A (AI medical imaging / breast) Tags: AI mammography.

Predicting MSI in colorectal cancer with AI: when CT and histology speak of biology

⚖️ Transparency notice: this article was written with AI assistance and reviewed by the author, a medical oncologist. The uncomfortable question before deciding A patient with newl.

RIBOLARIS: ribociclib in neoadjuvant and adjuvant therapy for high-risk HR+ breast cancer

Title: RIBOLARIS: ribociclib in neoadjuvant and adjuvant settings for high-risk HR+ breast cancer — a paradigm shift Type: B (clinical / real-world) Tags: ribociclib, CDK4/6, HR+ b.

Synthetic medical data: the FDA proposes 7 criteria to use them without fooling ourselves

Title: Synthetic medical data: the FDA proposes 7 criteria to use them without fooling ourselves Type: C (AI / data governance / LOPD) Tags: synthetic data, medical AI, FDA, privac.

KRAS G12C Responds Better to Immunotherapy: The KRAS Subtype Matters in NSCLC (Real-World)

Title: KRAS G12C responds better to immunotherapy: the KRAS subtype matters in NSCLC (real-world) Type: B (clinical / real-world) Tags: KRAS, NSCLC, immunotherapy, biomarkers, real.

When the breast and the axilla don’t agree: discordance after neoadjuvant therapy in TNBC

Reference: Discordance between Breast and Axillary Responses After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Biol Ther. 2026. PMID: 42624979.